- Home
- NRGV vs CRBP Comparison
NRGV vs CRBP Comparison
Compare NRGV & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- CRBP
- Stock Information
- Founded
- NRGV 2017
- CRBP 2009
- Country
- NRGV United States
- CRBP United States
- Employees
- NRGV N/A
- CRBP N/A
- Industry
- NRGV Industrial Machinery/Components
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- CRBP Health Care
- Exchange
- NRGV Nasdaq
- CRBP Nasdaq
- Market Cap
- NRGV 133.4M
- CRBP 114.8M
- IPO Year
- NRGV N/A
- CRBP N/A
- Fundamental
- Price
- NRGV $1.91
- CRBP $9.89
- Analyst Decision
- NRGV Buy
- CRBP Strong Buy
- Analyst Count
- NRGV 3
- CRBP 10
- Target Price
- NRGV $1.58
- CRBP $53.22
- AVG Volume (30 Days)
- NRGV 1.9M
- CRBP 97.4K
- Earning Date
- NRGV 08-07-2025
- CRBP 11-06-2025
- Dividend Yield
- NRGV N/A
- CRBP N/A
- EPS Growth
- NRGV N/A
- CRBP N/A
- EPS
- NRGV N/A
- CRBP N/A
- Revenue
- NRGV $51,716,000.00
- CRBP N/A
- Revenue This Year
- NRGV $314.58
- CRBP N/A
- Revenue Next Year
- NRGV $39.00
- CRBP $220.04
- P/E Ratio
- NRGV N/A
- CRBP N/A
- Revenue Growth
- NRGV N/A
- CRBP N/A
- 52 Week Low
- NRGV $0.60
- CRBP $4.64
- 52 Week High
- NRGV $2.70
- CRBP $56.93
- Technical
- Relative Strength Index (RSI)
- NRGV 62.79
- CRBP 56.38
- Support Level
- NRGV $2.00
- CRBP $9.50
- Resistance Level
- NRGV $2.33
- CRBP $10.17
- Average True Range (ATR)
- NRGV 0.16
- CRBP 0.59
- MACD
- NRGV 0.02
- CRBP -0.02
- Stochastic Oscillator
- NRGV 54.84
- CRBP 56.74
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.